Glioblastoma Multiforme Trials
Newly Diagnosed Glioblastoma Trials
- Newly Diagnosed Glioblastoma Multiforme - A Phase II study of Avastin® (Bevacizumab) and Tarceva® (Erlotinib) after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma multiforme without MGMT promotor methylation (more information)
- Newly Diagnosed Glioblastoma Multiforme (Peptide Vaccine Immunotherapy) -Phase llb clinical trial of an investigational vaccine (ICT-107) for the treatment of newly diagnosed GBM following resection and chemo-radiation. (more information)
- Newly Diagnosed Glioblastoma Multiforme and Unmethylated MGMT - Core Study -Cilengtide in subjects with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter - a multicenter. open-label Phase II study, investigating two cilengtide regimens in combination with standard treatment temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy. (more information)
Recurrent Glioblastoma Trials
- Recurrent Glioblastoma Multiforme: RTOG 0929 - A Randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent (temozolomide resistant) glioblastoma (RTOG 0929). (more information)
- Initial Recurrence of Glioblastoma Multiforme - A Phase 2 study of MEDI-575 in adult subjects with recurrent glioblastoma multiforme (more information)
